Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.
Rating Reviews
Rating is calculated based on
1
review and is evolving.
Pros: The leadership at Aignostics is incredibly transparent and supportive, which is huge for a growing tech startup. They really trust their team members, giving us autonomy as AI Engineers to work on challenging problems in digital pathology. The collaborative spirit is strong, and there are ample opportunities to learn from smart colleagues and advance your skills in medical AI.
Cons: While the leadership is great, sometimes communication flow across departments, especially regarding project roadmap changes, could be a bit smoother. As a fast-paced healthcare AI company, the workload for AI Engineers can be intense during critical project phases, which occasionally impacts work-life balance a bit.
Advice to Management: Continue fostering transparent communication channels, especially as the company scales. Consider initiatives to help manage workload peaks for engineering teams to ensure sustainable high performance for AI Engineers.
Show more
What is the day-to-day working culture like at Aignostics, especially for AI Engineers in Berlin?
The culture at Aignostics is collaborative and focused on innovation, typical for a growing AI startup. Team members are encouraged to share ideas and contribute to projects, fostering a dynamic environment for AI Engineers working on medical diagnostics.
DE
